First, besides promoting the expression of SCD1 which is the downstream effector for anti‐ferroptosis, LXRα also upregulated the levels of miR‐181a‐5p and its RNA‐binding protein FUS,[27] thereby enhancing the enrichment of miR‐181a‐5p in tumor‐released EVs. This evidence concerns the gene NR1H3 and neoplasm.